Fmr LLC Werewolf Therapeutics, Inc. Transaction History

Fmr LLC

$1.68 Trillion
Q2 2025

A detailed history of Fmr LLC transactions in Werewolf Therapeutics, Inc. stock. As of the latest transaction made, Fmr LLC holds 11,284 shares of HOWL stock, worth $18,505. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,284

Previous 4,461 152.95%

Holding current value

$18,505

Previous $4,000 200.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$0.63 - $1.42 $4,298 - $9,688	6,823 Added 152.95%	11,284 $12,000
Q1 2025 May 12, 2025	BUY	$0.97 - $1.68 $2,551 - $4,418	2,630 Added 143.64%	4,461 $4,000
Q4 2024 Feb 13, 2025	BUY	$1.48 - $3.63 $469 - $1,150	317 Added 20.94%	1,831 $2,000
Q3 2024 Nov 13, 2024	BUY	$1.71 - $2.95 $2,583 - $4,457	1,511 Added 50366.67%	1,514 $3,000
Q2 2024 Aug 13, 2024	BUY	$2.34 - $6.75 $7 - $20	3 New	3 $0
Q1 2023 May 11, 2023	BUY	$1.98 - $4.3 $4,158 - $9,030	2,100 New	2,100 $5,000
Q3 2022 Nov 10, 2022	SELL	$4.14 - $7.42 $752,233 - $1.35 Million	-181,699 Reduced 35.02%	337,073 $1.52 Million
Q2 2022 Aug 12, 2022	BUY	$3.43 - $5.98 $469 - $819	137 Added 0.03%	518,772 $2.12 Million
Q1 2022 May 13, 2022	BUY	$3.71 - $12.22 $548,712 - $1.81 Million	147,901 Added 39.89%	518,635 $2.28 Million
Q4 2021 Feb 14, 2022	BUY	$11.48 - $17.65 $1.52 Million - $2.33 Million	132,234 Added 55.44%	370,734 $4.42 Million
Q3 2021 Nov 15, 2021	SELL	$13.89 - $20.31 $1.06 Million - $1.55 Million	-76,500 Reduced 24.29%	238,500 $4.09 Million
Q2 2021 Aug 13, 2021	BUY	$11.6 - $17.44 $3.65 Million - $5.49 Million	315,000 New	315,000 $5.49 Million

Others Institutions Holding HOWL

# of Institutions

Shares Held

23.6M

Call Options Held

Put Options Held

View Full List

About Werewolf Therapeutics, Inc.

Ticker HOWL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,529,400
Market Cap $48.4M
Description
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional ...

More about HOWL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account